A growing list of contemporary phase 3 trials have shown that more drugs (quadruplet therapies) are superior to less drugs ...

"We are well aware that four-drug regimens with anti-CD38 monoclonal antibodies, lenalidomide, proteasome inhibitors, and ...

Combining the oral drug ixazomib and lower-dose lenalidomide shows important reductions in neutropenia and peripheral ...

TORONTO -- A three-drug combination involving the B-cell maturation antigen (BCMA)-CD3 bispecific antibody elranatamab ...

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk This multicenter, single ...

Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...

An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.

Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials, ...

Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary ...

Please provide your email address to receive an email when new articles are posted on . The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or ...

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years Subgroup analysis from Phase 3 ...